

KAREN LOUISE WEIHS, M.D.

CHRONOLOGY OF EDUCATION:

Undergraduate Education

University of Northern Iowa, Cedar Falls, Iowa 1975, B.A., Biology & Chemistry

Medical Education

The University of Iowa College of Medicine, Iowa City, Iowa 1979, M.D.

Postgraduate Training

Family Medicine, PGY-1 and -2, York Hospital, York, PA 1979-1981

Family Medicine, PGY-3 Hunterdon Medical Center, Flemington, NJ 1981-1982

Family Therapy Externship, Ackerman Institute, New York, New York 1981-1982

Family Therapy Supervision & Theory – McMaster Model, Brown Univ. 1982-1983, 1984-1985

General Psychiatry-University of Wisconsin, Madison, Wisconsin 1986-1989

Child Psychiatry-University of Wisconsin, Madison, Wisconsin 1989-1991

Training Component of Scientist Development Award for Clinicians (K20)

Biostatistics – 2 semesters, Epidemiology
Foundation for Advanced Education in the Sciences,
NIH, Bethesda, MD 1991-1992

Advanced statistics and Statistical Analysis Systems (SAS) – 5 graduate courses
Department of Psychology and Business Administration,
The George Washington University 1992-1994

Family Research Consortium Fellow, Iowa State University; Ames, Iowa July/August 1993

Mind-Body Medicine Professional Training Program; Berkeley, CA January 28 – February 5, 2006

Enhancing Team Effectiveness: A Professional Development Program for Health Professions Faculty

Jointly sponsored by the Assn of Am Medical Colleges (AAMC) and Harvard Medical
School, Dept of Continuing Medical Education.

September 15-20, 2006
Seminar in Team Dynamics , Keystone Resort & Conference Center, Lakewood, CO

December 11, 2006
Teams in Action , Webcast Discussion

February 15-17, 2007

Colloquium – Lessons Learned , Jury’s Washington Hotel, Washington, DC

Survivorship Education for Quality Cancer Care, Professional Development Workshop, City of
Hope, San Diego, CA July 13-15, 2007

Learning to Lead, University of Arizona, College of Medicine Faculty Leadership Program
Sept, 2010 – May 2012

EMPLOYMENT:

Full-Time Academic Positions:

Instructor, Department of Family Medicine, Brown University Providence, Rhode Island	1982-1984
Assistant Professor, Department of Family Medicine, Brown University Providence, Rhode Island	1984-1986
Instructor, Division of Child Psychiatry, Department of Psychiatry University of Wisconsin; Madison, Wisconsin	February – June, 1991
Assistant Professor, Department of Psychiatry & Behavioral Sciences The George Washington University, Washington, DC	1991-2002
Associate Professor, Department of Psychiatry & Behavioral Sciences The George Washington University, Washington, DC	2002-2005
Associate Clinical Professor of Psychiatry and Behavioral Sciences The George Washington University School of Medicine Washington, D.C.	2005 – Present
Associate Professor, Department of Psychiatry University of Arizona, College of Medicine; Tucson, AZ	2005 – 2008
Associate Professor with tenure, Department of Psychiatry University of Arizona, College of Medicine; Tucson, AZ	2008 – 2013
Associate Professor of Family and Community Medicine University of Arizona, College of Medicine; Tucson, AZ	2009 – 2013
Associate Chair for Research, Department of Psychiatry	2012 – present
Professor with tenure, Department of Psychiatry University of Arizona, College of Medicine; Tucson, AZ	2013

Part-Time Academic Positions

Clinical Instructor, Department of Family Medicine

University of Wisconsin; Madison, Wisconsin 1988-1991

Part-Time Employment

Family Physician, Dean Medical Center, Madison, WI 1986-1988
General Physician, Planned Parenthood of WI, Madison, WI 1986-1988
General Physician, Tellurian Detoxification Unit, Madison, WI 1988-1991
Adult & Child Psychiatrist, Mental Health Center, Madison, WI 1988-1991
Consulting and Private Practice Psychiatrist, Madison, WI 1989-1991

HONORS

University of Northern Iowa Science Symposium Scholar 1971 - 1975
State of Iowa Scholar 1973 - 1975
Graduated Suma cum Laude, University of Northern Iowa 1975
Regional Trustee, The American Medical Student Association 1978
Outstanding Educator Award- Department of Family Medicine, Brown University 1986
Charter Fellow, American Assn. of Directors of Psychiatric Residency Training 1990
Best Poster, Conference on the (Non) Expression of Emotions in Health and Disease 1996
Tilburg, Holland
Fellow, American Psychiatric Association 2003
Fellow, Academy of Behavioral Medicine Research 2004
Comprehensive Member, Arizona Cancer Center 2004
The Outstanding Clinical Care Award, American Psychosocial Oncology Society 2008
Who's Who Among Executives and Professionals "Honors Edition" 2008 - 2009
Senior Women's Health Scholar, Women's Center of Excellence, 2009
University of Arizona College of Medicine
Best Doctors Awardee 2011, 2012, 2013
Awardee, Resnick Family Lecturer in Psychiatry and Palliative Care
The George Washington University 2012
President-Elect, American Psychosomatic Society 2013

PROFESSIONAL CERTIFICATIONS:

American Board of Family Practice Certification 1982;
Recertified-1988/1995/2002/2009
American Board of Psychiatry and Neurology
Certification in Psychiatry 1994

American Board of Psychiatry and Neurology
Certification in Hospice and Palliative Medicine 2012

SERVICE/OUTREACH (since May 2009):

Local/State Service/Outreach

Founder and Leader, Psychiatry Department Research Investigators Group
2005 – Present

Founder and leader, MESH – Mechanisms of Emotion, Social Relationships and Health
Interdisciplinary Developing Research Program, Clinical and Translational Science Institute
BIO5 University of Arizona 2009 - present

Medical Director, Psychosocial Oncology Services 2006 – Present
University of Arizona Medical Center

Director, Supportive Care Section, Cancer Prevention and Control June 2007 – 2010
Program Arizona Cancer Center

Director, Psychosocial Oncology Section, Biobehavioral and Social June 2010 – Present
Science Research Developing Program, Arizona Cancer Center

Coordinator, Partners in Survival: Men Supporting Women with Cancer, 2007 – 2011
Quarterly Saturday workshops, Arizona Cancer Center at University Medical Center-North

Speaker, First Annual Survivorship Conference, June, 2009
Acceptance of Emotions and Connection to Others Strengthen the Whole Person and the Family,
presentation for Sunstone Cancer Support Centers, Tucson, AZ

American Red Cross Blood Donor, every 56 days 1998 – Present

Pima County Democratic Party Volunteer 2004 – Present

National/International Service/Outreach

American Psychosomatic Society
National Council Member 2009 – 2012

Co-Chair, National Conference sponsored by Am Psychosomatic Society October 2012
Toward Precision Cancer Care: Biobehavioral Contributions to the Exposome
Chicago, IL

National Advisory Board, Wynne Center for Family Research Institute for the Family, University of Rochester, Rochester, NY	2007-2010
Scientist Reviewer, U.S. Army Medical Research and Material Command, Breast Cancer Research Program - Behavioral and Social Science Committee	2009
Alliance for Quality Cancer Care – American Psychosomatic Society representative	2009 – present
National Pharmacy and Therapeutics Committee, CVS-Caremark, Inc.	2001-Present

Editorial Board/Ad Hoc Scientific Reviewer

Advisory Editor: Families, Systems and Health

Reviewer for the following journals:

- Annals of Behavioral Medicine
- Families, Systems and Health
- Journal of Clinical Psychiatry
- Journal of Family Psychology
- Journal of the National Cancer Institute
- Journal of Psychosomatic Research
- Lancet Oncology
- Psycho-Oncology
- Psychosomatic Medicine
- Psychosomatics

Departmental Committees (2009 - present)

Department of Psychiatry, Promotion and Tenure Committee	Dec. 2009 - Present
--	---------------------

College Committees (2009 – present)

Co-Director, Psychosomatic Medicine Interest Group, University of Arizona, College of Medicine	Fall 2007–Spring 2011
---	-----------------------

Strategic Council Champion, University of Arizona Health Network	May 2011 – Present
--	--------------------

Clinical Operations Committee, Arizona Cancer Center at University Arizona Cancer Center at University Medical Center	2007 - Present
--	----------------

University Committees (2009 – present)

Scientific Advisory Committee member, R25T Cancer Prevention and Control Training Program Arizona Cancer Center	January 2011 - 2015
Scientific Advisory Board – Retreat participant Arizona Cancer Center	Jan. 2010; March 2012
Chairperson, Advisory Committee for University of Arizona, Clinical and Translational Science Center(CATS)	Nov. 2009 – 2011
Member, Clinical and Translational Science Center Advisory Committee, University of Arizona, College of Medicine	Spring 2008 – Nov. 2009
Junior Faculty Mentoring Committee, Arizona Cancer Center,	Fall 2007 – Present
Grant Reviewer, American Cancer Society Institutional Research Grants Arizona Cancer Center	Fall 2006 - 2008
Chair, Supportive Care Coordinating Team, Arizona Cancer Center	2006 – Present

Other Committees

American Psychosomatic Society	
Chair, Membership Committee	2008- 2010
Member, Program Committee	2007-2010
Nominating Committee	2011 – 2014
Alliance for Quality Cancer Care – Research Committee	2009 – present

PUBLICATIONS: ORIGINAL RESEARCH – PEER-REVIEWED JOURNAL ARTICLES

- 1) Robbins ML, Mehl MR, Smith HL, Weihls KL (2013) Linguistic Indicators of Patient, Couple, and Family Adjustment to Breast Cancer; *PsychoOncology*. Volume 22, Issue 7, July 2013, Pages: 1501–1508. DOI: 10.1002/pon.3161
- 2) Badger TA, Segrin C, Hepworth JT, Pasvogel A, Weihls KL, Lopez AM (2013) Telephone-Delivered Health Education and Interpersonal Counseling Improve Quality of Life for Latinas with Breast Cancer and Their Supportive Partners; *PsychoOncology* . Volume 22, Issue 5, May 2013, Pages: 1035–1042. DOI: 10.1002/pon.3101
- 3) Marshall, C.A., Curran, M.A., Koerner, S.S., Weihls, K.L., Hickman, A., & García, F. (2013). Information and support for co-survivors during or after cancer treatment: Consideration of *Un*

Abrazo Para la Familia as a model for family-focused intervention in cancer rehabilitation. *WORK: A Journal of Prevention, Assessment, and Rehabilitation*. 46(2)

- 4) Kogan, A.V., Allen, J.J.B., Weihls, K.L., Cardiac Vagal Control as a Prospective Predictor of Anxiety in Women Diagnosed with Breast Cancer, *Biological Psychology* (2012), Volume 90, Issue 1, April 2012, Pages 105-111. doi:10.1016/j.biopsycho.2012.02.019
- 5) Marshall, C.A., Badger, T.A., Curran, M.A., Koerner, S.S., Larkey, L.K., Weihls, K.L., Verdugo, L., & García, F. (2012). Un Abrazo Para la Familia: Providing low-income Hispanics with education and skills in coping with cancer and caregiving. *Psycho-Oncology*. Volume 22, Issue 2, February 2013, Pages: 470–474. Doi:10.1002/pon.2108
- 6) Howe GW, Hornberger AP, Weihls KL, Moreno F, Neiderhiser JM. (2011). Higher-order structure in the trajectories of depression and anxiety following sudden involuntary unemployment. *Journal of Abnormal Psychology*. 121(2); 325-338.
- 7) Weihls KL, Wert JM. (2011). A Primary Care Focus on the Treatment of Patients with Major Depressive Disorder; *The American Journal of Medical Sciences*. 342(4); 324-330.
- 8) Robbins ML, Focella ES, Kastle S, López AM, Weihls KL, Mehl MR (2011) Brief Report: Naturalistically Observed Swearing, Emotional Support and Depressive Symptoms in Women Coping with Illness, *Health Psychology*. 30(6):789-792. doi:10.1037/a0023431
- 9) Marshall, C.A., Weihls, K.L., Larkey, L.K., Badger, T.A. Koerner, S.S., Curran, M.A., Pedroza, R., & García, F. (2011). “Like a Mexican wedding”: The psychosocial intervention needs of predominately Hispanic low-income female co-survivors of cancer. *Journal of Family Nursing*, 17 (3), 380 - 402. DOI: 10.1177/1074840711416119.
- 10) Marshall, C.A., Larkey, L.K., Curran, M.A., Weihls, K.L., Badger, T.A., Armin, J., & García, F. (2011). Considerations of culture and social class for families facing cancer: The need for a new model for health promotion and psychosocial intervention. *Families, Systems, & Health*, 29(2), 81–94. DOI: 10.1037/a0023975
- 11) Lane RD, Weihls KL (2010) Freud’s Antiquities. *Psychodynamic Practice*, 16(1): 77-78.
- 12) Hess LM, Malone DC, Reed PG, Skrepnek GH, Weihls KL (2010) Preferences of patients and oncologists for advanced ovarian cancer treatment-related health states. *Health Outcomes Research in Medicine*, 1(1):E51-E59. doi:10.1016/j.ehrm.2010.02.001
- 13) Michael YL, Carlson NE, Chlebowski RT, Aickin M, Weihls KL, Ockene JK, Bowen DJ, Ritenbaugh C. (2009) Influence of stressors on breast cancer incidence in the Women’s Health Initiative, *Health Psychology*, 28(2): 137-146.

- 14) Weihls KL, Enright TM, Simmens S (2008) Response to Coyne: Was it shown that close relationships predict breast cancer outcome? *Psychosomatic Medicine*, 70: 737-740.
- 15) Weihls KL, Enright T, Simmens S. (2008). Close relationships and emotional processing predict decreased mortality in women with breast cancer: Preliminary Evidence. *Psychosomatic Medicine*, 70(1): 117 – 124.
- 16) Politi MC, Enright TM, & Weihls KL. (2007). The effects of age and emotional acceptance on distress among breast cancer patients. *Supportive Care in Cancer*, 15(1), 73-79. DOI: 10.1007/s00520-006-0098-6.
- 17) Weihls KL, Mizrahi J, Hunt M, Enright T, Simmens S. (2005). Dependable social relationships predict overall survival in Stage II and III breast carcinoma patients. *Jl of Psychosomatic Research*, 59(5): 299-306. DOI information 10.1016/j.jpsychores.2004.12.002
- 16) Liebowitz MR, DeMartinis NA, Weihls K, Longborg PD, Smith WT, Chung H, Fayyad,R, Clary CM. (2003). Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study. *Jl of Clin Psychiatry* 64(7): 785-792.
- 17) Kimmel PL, Chawala LS, Amarasinghe A, Peterson RA, Weihls KL, Simmens SJ, Allyne S, Burke HB, Cruz I, Veis JH. (2003). Anthropometric measures, cytokines and survival in haemodialysis patients. *Nephrology Dialysis Transplantation* 18(2): 326-32.
- 18) Liebowitz MR, DeMartinis NA, Weihls K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM (2003) Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study. *Jl of Clinical Psychiatry* (64)7:785-792.
- 19) Schneider LS, Nelson D, Clary CM, Newhouse P, Krishman KRR, Shiovitz T, Weihls K and The Sertraline Elderly Depression Study Group (2003). An eight-week, multicenter parallel group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. *American Journal of Psychiatry* 160: 1277 – 1285.
- 20) (*Karen Weihls was a member of the Sertraline Pediatric Depression Study Group.*) Wagner KC, Ambrosini R, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D, Sertraline Pediatric Depression Study Group (2003). Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials. *JAMA* 290 (8): 1033 – 1041.

- 21) Weihs K, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RMJ, Metz A.(2002). Long-term treatment with bupropion SR effectively prevents the relapse and recurrence of depression. *Biological Psychiatry*, 51(9): 753-761.
- 22) Weihs K, Enright T, Simmens S, Reiss D. (2000). Negative affectivity, restriction of emotions and site of metastases predict mortality in recurrent breast cancer. *Jl. of Psychosomatic Research*, 49: 59-68.
- 23) Kimmel PL, Peterson RA, Weihs KL, Shidler N, Simmens SJ, Alleyne S, Cruz, I, YanovshI JA, Veis JH, Phillips RM. (2000). Marital conflict, gender and survival in urban hemodialysis patients. *J Am Soc Nephrology* 11:1518-1525.
- 24) Kimmel PL, Peterson, RA, Weihs KL, Simmens, SJ, Alleyne, S, Cruz, IJA, Veis JH. (2000). Multiple measurements of depression predict mortality in longitudinal study of chronic hemodialysis outpatients. *Kidney International*, 57: 2093-2098.
- 25) Weihs KL, Settle E, Batey SR, Houser TL, Donahu, RMJ, Ascher JA (2000). Comparison of the safety and efficacy of bupropion sustained release and paroxetine in elderly depressed outpatients. *Journal of Clinical Psychiatry*, 61(3):196-202.
- 26) Ginexi EM, Weihs K, Simmens SJ, Hoyt DR. (2000). Natural disaster and depression: A prospective investigation of reactions to the 1993 midwest floods, *Jl of Community Psychology*, 28(4): 495-518.
- 27) Kimmel PL, Varela MP, Peterson PA, Weihs KL, Simmens SJ, Alleyne S, Amarashinge A, Mishkin GJ, Cruz I, Veis JH (2000). Interdialytic weight gain and survival in hemodialysis patients: Effects of duration of ESRD diabetes mellitus. *Kidney International*; 57 (3): 1141-1151.
- 28) Weihs KL, Enright TE, Simmens SJ. (1999). Marital satisfaction and emotional adjustment to breast cancer. *Journal of Psychosocial Oncology*, 17 (1):33-49.
- 29) Clayton AH, Clavet GJ, McGarvey EL, Warnock JK, Weihs KL. (1999). Assessment of sexual functioning during the menstrual cycle. *Jl of Sex & Marital Therapy*, 25: 281-291.
- 30) Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Veis J, Cruz I.(1998) . Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. *Kidney International*, 54:245-254.

- 31) Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyn S, Cruz I, Yanovski JA, Veis JH. (1998). Immunologic function and survival in hemodialysis patients. *Kidney International*, 54: 236-244.
- 32) Hoyt DR, Conger RD, Valde JG, Weihs K. (1997). Psychological distress and help seeking in rural America. *American Journal of Community Psychology*, 25(4) 449-470.
- 33) Kimmel PL, Peterson RA, Weihs KL, Simmens SJ , Boyle DH, Umana W, Kovac JA, Alleyne S, Veis J, Cruz I. (1996). Psychological functioning, quality of life and behavioral compliance in patients beginning hemodialysis, *J. Am. Soc. Nephrology* 7(10):2152-9.
- 34) Kimmel PL, Peterson RA, Weihs K, Simmens SJ, Boyle DH, Verme D, Umana W, Veis J, Alleyn S, Cruz I. (1995). Behavioral compliance with dialysis prescription in hemodialysis patients *J. Am. Soc. Nephrology*, 5(10):1826-1834.
- 35) Kimmel PL, Weihs K, Peterson RA, Simmens SJ, Boyle, DH, Cruz I, Umana W, Alleyne S, Veis J. (1995). Aspects of quality of life in hemodialysis patients. *J. Am. Soc. Nephrology*, 6:1418-1426
- 36) Weihs K, Chapados JT. (1986). Interviewing skills training - A study. *Social Science and Medicine*, 23:31-34.

REVIEWS – PEER-REVIEWED JOURNAL ARTICLES:

- 1) Weihs K, Fisher L, Baird M. (2002). Families and the management of chronic disease; Report for the Committee on Health and Behavior: Research Practice and Policy; Institute of Medicine, National Academy of Sciences, Families, Systems and Health, 20(1): 7 – 46.
- 2) Fisher L, Weihs KL (2000). Family relationships: A key for improving outcomes in chronic disease, *Jl. of Family Practice*. 49(6): 561 – 566.
- 3) Frank JB, Weihs K, Minerva E., Lieberman DZ. (1998). Women's mental health in primary care. Depression, anxiety, somatization, eating disorders, and substance abuse. [Review][227 refs] *Medical Clinics of North America*. 82(2):359-89.
- 4) Kimmell PL, Weihs K, Peterson RA. (1993). Survival in hemodialysis patients: The role of depression. *J. Am. Soc. Nephrology*. 3:12-27.

OTHER PUBLICATIONS (BOOK REVIEWS/LETTERS/EDITORIALS/REPORTS):

- 1) Michael YL, Carlson NE, Bowen DJ, Ritenbaugh C, Chlebowski RT, Weihs KL, Ockene JK. (2011). "Re: Invited Commentary: Personality as a Causal Factor in Cancer Risk and Mortality: Time to Retire a Hypothesis?" *American Journal of Epidemiology* **173**(6): 716.
- 2) Weihs K, Enright T, Simmens S (2008) Response to, "Was it shown that 'Close relationships and emotional processing predict decreased mortality in women with breast cancer?', A critique of Weihs, et al.", *Psychosomatic Medicine* 70: 737-740.
- 3) Weihs K (2007). Book review of : *Individuals, Families and the New Era of Genetics: A biopsychosocial perspective*; *Families, Systems & Health*, Vol 25(2): 223-226.
- 4) Silver M. (2004). Breast cancer husband. Citation of research by KL Weihs, M.D. pp. 55-56; Published by Rodale Press.
- 5) Maloy K, Reiss D, Weihs K . (2003) Risk and resilience in children of depressed parents: Exploring the potential for implementing and financing screening and preventive services in multiple settings SAMHSA Task Order 23: Year One Draft Interim Report.
- 6) Plese NK, Weihs KL(2003). How families matter in health: Challenges of the evolving 21st- century family. *The Pfizer Journal* 7(1): 24-25.
- 7) Weihs KL, Settle E, Batey SR, Houser TL, Donahue RMJ, Ascher JA (2001). Type II error and antidepressants: Reply, *Journal of Clinical Psychiatry*, 62(5):374-375.
- 8) Weihs K, Fisher L, Baird M. (2001). Families and the management of chronic disease, Report for the Committee on Health and Behavior: Research Practice and Policy; Institute of Medicine, National Academy of Sciences.
- 9) Weihs K. (1999). Book review: Family caregiving in mental illness, by Harriet Lefley (Sage Press 1996); *Families, Systems and Health*, 16 (4): 455-457.
- 10) Weihs K. (1997). Commentary: Mental health care in the primary care setting; *Families, Systems and Health*,15:37-39.
- 11) Weihs K. (1996). Dilemmas in coping with breast cancer; *Families, Systems and Health*, 14 (1): 89-93.
- 12) Weihs K. (1984). Bluefish and scromboid poisoning, *Jl of Family Practice*, 18:835.
- 13) Weihs K, Loxterkamp D. (1978) Involved students preparing to serve. *Commitment*. Summer; 3 (3):20-21.

BOOKS/MANUALS:

Howe GW, Matthey M, Weihls KL. (2005) .Contextual assessment of stressful events in childhood – Basic Principles.

This 27 page manual describes the concepts and methods for interviewing children and their parents to assess and score the contextual severity of threat from stressful life events and difficulties in children aged 10 – 14. Adapted from the Life Events and Difficulties Interview (Brown & Harris, 1978) and the Adolescent LEDS (Frank, E and Anderson, B., 1995). Available upon request from the authors.

Howe GW, Matthey M, Weihls, KL. (2005). Contextual assessment of stressful events in childhood – Scoring Manual and Dictionary.

This 436 page document provides detailed descriptions of prototypes for rating the contextual severity of threat from stressful life events in eleven domains including Education, Work, Reproduction, Housing/Residence/Neighborhood, Crime/Legal, Health, Romantic Relationships, Parents, Friends/Leisure, Other Relationships & Pets/Death/Miscellaneous. Subdomains in each section include prototypes as well as factors for increasing/decreasing threat in relation to the standard prototype, in order to provide a reliably reproducible scoring system for severity of threat. Available upon request from the authors.

Howe GW, Matthey M, Weihls, KL. (2005). Contextual assessment of stressful events in childhood – Interview Guide and Training Materials. Available upon request from the authors.

BOOK CHAPTERS:

- 1) Weihls KL, Politi M. (2005). Families and cancer, in Crane DR & Marshall ES (eds.) Handbook of Families and Health: Interdisciplinary Perspectives, Thousand Oaks, CA: Sage Publications. pp. 3 – 18.
- 2) Weihls KL, Politi M, Menahan KD, Lincoln JM. (2005). The needs of the patient and family, in relating to breast cancer: A biopsychosocial model of adaptation in Roses, DF (ed.) Breast Cancer, 2nd Edition, Churchill Livingstone, A Division of Harcourt Brace & Company. pp. 761-776.

- 3) Weihs K, Reiss D.(2000). Family reorganization in response to cancer: A developmental perspective, in Cooper, C.; Baider, L; Kaplan-DeNour, A. (eds.) Cancer and the Family, Second edition, John Wiley & Sons, Ltd., Chichester, England. pp. 134 – 162.
- 4) Weihs KL, Menehan KD, Lincoln JM. (1999). The needs of the patient and family in relating to breast cancer: A biopsychosocial model of adaptation, in Roses, DF (ed.) Breast Cancer , Churchill, London, pp. 637-651.
- 5) Weihs K.(1997). A woman with breast cancer in Mc Daniel, SH; Hepworth, J; Doherty, W.(eds.) The Shared Experience of Illness, Guilford Press, New York, pp.195-204.
- 6) Weihs K, Reiss D.(1996). Family reorganization in response to cancer: A developmental perspective in Cooper, C.; Baider, L; Kaplan-DeNour, A. (eds.) Cancer and the Family, John Wiley & Sons, Ltd., Chichester, England, pp. 3-30.
- 7) Weihs K, Kingsolver K. (1986). Systems-oriented counseling , in Crouch M., Roberts L.(eds.) The Family In Medical Practice: A Family Systems Primer, Springer-Verlag, New York, NY, pp. 140-174.
- 8) Weihs K. (1986). Family interventions in failure to thrive, in Doherty, W., Baird, M., Family Centered Medical Care: A Clinical Casebook, Guilford Press, New York NY, pp. 223-227.

PUBLISHED ABSTRACTS (PEER REVIEWED):

- 1) Reed, R. G., Butler, E. A, & Weih, K. L. (submitted). Examination of instability in perceived stress over time as predictive of physical well-being in women with breast cancer. Poster to be presented at the American Psychosomatic Society 72nd Annual Scientific Meeting, San Francisco, CA.
- 2) Weihs KL, Lane RD, Stanton AS, Lin JC, Pichler ER. (2012) Breast Cancer Patients Who Report Greater Security and Support in Close Relationships have Higher Emotional Awareness. *Psychosomatic Medicine*; 74(3) A85.
- 3) Lane RD, Weihs KL, Stanton AL, Hartz VL, Fort CL, (2012) Computerized Scoring of Emotional Awareness Content in Writing Samples by Patients with Breast Cancer. *Psychosomatic Medicine*; 74(3) A103.

- 4) Robbins ML, Mehl MR, Smith HL, Weihls KL. (2012) The daily conversations of couples coping with breast cancer: Content and links to adjustment. *Psychosomatic Medicine*; 74(3) A40.
- 5) Robbins, M. L., Mehl, Matthias, M. R., Smith, H. L., & Weihls, K. L. (2012, June). Linguistic Indicators of Patient, Couple, and Family Adjustment to Breast Cancer. Poster to be presented at the 6th Biennial Cancer Survivorship Research Conference, Arlington, VA.
- 6) Weihls KL, Curran MA, Young VJ, Simmens SJ (2011) Marital biography and affection predict trajectories of physical well-being after breast cancer. Abstract 1246. APS Meeting Abstracts- Proceeding, 69th Annual Scientific Meeting, Abstract 1246 p. A27.
- 7) Kogan AV, Allen JJB, O'Donnell R, Brody AE, Weihls KL (2011) Cardiac vagal control as a prospective predictor of anxiety in women diagnosed with breast cancer. APS Meeting Abstracts- Proceeding, 69th Annual Scientific Meeting, Abstract 1247 p. 16.
- 8) Pozner A, Allen JB, O'Donnell R, Brody AE, Weihls KL. (2010). Resting cardiac vagal control and quality of partner relationship in women with newly diagnosed breast cancer. Abstract 1489. APS Meeting Abstracts- Proceeding, 68th Annual Scientific Meeting, 72(3), p. A49.
- 9) Nettles CD, Howe GW, Weihls KL, Moreno FA. (2010). Vulnerability to stress induced depression after job loss: testing variation by 5-HTTLPR gene. Abstract 1544. APS Meeting Abstracts- Proceeding, 68th Annual Scientific Meeting, 72(3): p. A131.
- 10) Weihls KL, Frank DH, Roe DS, Nassarloo H, Carter CS. (2009). Oxytocin administration, but not social housing condition, reduces growth rate of human breast cancer xenografts (MCF7) in SCID mice. *Cancer Res*, 69(Suppl.): (2), p. 331s.
- 11) Weihls KL, Hsu P, Amico J. Close Relationship Quality in Breast Cancer Patients: Preparing to Test Oxytocin as a Biomarker. Proceedings of the Era of Hope Meeting, Department of Defense Breast Cancer Research Program Meeting, June 25-28, 2008; Baltimore, MD.
- 12) Weihls, KL. (2008) Severely stressful events, sexual abuse history, chronic anxiety, low emotion acceptance and low family cohesion: Main and moderated effects on mood disturbance in breast cancer patients. *Psychosomatic Medicine*, APS Meeting Abstracts- Proceeding, 66th Annual Scientific Meeting , 70(3), p. A44.
- 13) Weihls KL, Enright TM, Simmens, SJ. (2007) Preliminary evidence for unique effects of relationship support and emotional processing on mortality in women with breast cancer. *Psychosomatic Medicine*, APS Meeting Abstracts - Proceedings, 65th Annual Scientific Meeting, p. A112.

- 14) Weihls KL, Haynes P, Ayers T, Olson K, Howe GW. (2006). Severely stressful life events predict internalizing –externalizing symptoms and impairment. 56th Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Scientific Proceedings, p. 156.
- 15) Badger TA, Weihls KL, Enright TM, Krouse R. (2006). Interpersonal relationship quality in people with cancer. *Psycho-Oncology* 15 (suppl 1):S3.
- 16) Blyler D, Weihls KL.(2004). Negative affectivity, severe life events, and breast cancer recurrence. Oral presentation 3283.0, Social Sciences in Health- Proceedings of the 132nd Annual Meeting of the Am Public Health Assn.; November 8, 2004, Washington, DC. Abstract #1187.
- 17) Gentzler A, Howe G, Weihls K, and Rohrbeck C. (2003). The efficiency and effectiveness of combining checklist and contextual assessments of stressful life events, Society for Research on Child Development, Biennial Meeting, Online Program p. 4-061.
- 18) Goodale E, Weihls K, Ascher J, Richard N, Metz A. (2003). Long-term treatment with bupropion SR effectively prevents the relapse and recurrence of depression. *European Neuropsychopharmacology The Journal of the European College of Neuropsychopharmacology* Volume 13, Supplement 4, page: S258.
- 19) Liebowitz M, DeMartinis N, Weihls K, Chung H, Clary C. (2002). Results from a randomized, double-blind, multicenter trial of sertraline in the treatment moderate- to -severe social phobia (social anxiety disorder), *Eur Neuropsychopharmacology*; 12: S352-S352.
- 20) Weihls KL, Enright T, Simmens S. (2002). Low expression of negative affect and denial predict breast cancer recurrence; American Psychiatric Association 2002 Annual Meeting Syllabus & Proceedings Summary, p. 6.
- 21) Weihls KL, Enright T, Simmens S. (2002). High quality spousal or long-term partner relationships predict time to recurrence of breast cancer, after control for disease severity; *Psychosomatic Medicine*, 64(1): 107.
- 22) Weihls KL. (2001). Social support network size predicts breast cancer recurrence and mortality, after control for disease severity *Psychosomatic Medicine*, 63(1): 153.
- 23) Weihls KL. (2000). Disease severity, chronic anxiety, emotional constraint and emotional style fail to predict time from breast cancer diagnosis to recurrence; *Psychosomatic Medicine*, 62(1): 135.
- 24) Weihls K. (1999). Evaluation of bupropion SR and paroxetine in elderly depressed outpatients; *Biological Psychiatry* 45(1S-147S), pp. 75S.
- 25) Weihls K.(1997). Psychosocial risk factors for breast cancer progression and mortality: Review of the literature and new findings; *Psychosomatics* 38:(2) pp. 1997.

- 26) Peterson RA, Kimmel PL, Phillips TM, Weihs KL, Simmens SJ, Kovac JA, Shidler N. (1997). The association of immune variables with psychosocial variables in a dialysis population: initial results *Annals of Behavioral Medicine*, 1997 International Congress Supplement, p. C083.
- 27) Kimmel PL, Peterson R, Weihs K, Phillips T, Simmens S, Veis J, Cruz I. (1997). Hemodialysis (HD) patients' perception of psychological adjustment and well-being and compliance with dialysis prescription are associated with survival. *Jl Am Soc Nephrology*; 8: A0913-A0913 Suppl.
- 28) Kimmel PL, Peterson R, Weihs K, Phillips T, Simmens S, Veis J, Cruz I. (1997). Proinflammatory cytokines and T-cell function predict mortality and survival in hemodialysis patients, *Jl Am Soc Nephrology*; 8: A0915-A0915 Suppl.
- 29) Kimmel PL, Peterson R, Weihs K, Phillips T, Simmens S, Veis J, Cruz I. (1997). Dialyzer type is associated with survival in the absence of differences in circulating immune markers, *Jl Am Soc Nephrology*; 8: A0912-A0912 Suppl.
- 30) Weihs KL, Simmens S, Reiss D.(1996). Survival in recurrent breast cancer patients predicted by patient coping style, in Vingerhoets, AJJM; van Bussel, FJJ, Boelhouwer AJW The (Non) Expression of Emotions in Health and Disease Abstracts, Faculties Sociale Wetenschappen, Katholieke Universiteit Brabant, Tilburg, Netherlands, pp 123.
- 31) Kimmel PL, Peterson R, Weihs K, Simmens S, Kovac J, Veis J, Cruz. (1996). Compliance with dialysis prescription, social support (SS), quality of life (QOL) and decreased depression level are associated with enhanced survival in inner city hemodialysis (HD) patients, *Jl Am Soc Nephrology*, 7 (9): A1016-A1016.
- 32) Kimmel PL, Weihs K, Peterson R, Simmens S, Boyle D, Umana W, Veis J, Cruz. (1995). Compliance and social support enhance survival in hemodialysis patients, *Jl Am Soc Nephrology*; 6 (3): 541-541: Special Issue
- 33) Kimmel PL, Weihs K, Peterson R, Simmens S, Boyle D, Umana W, Veis J, Cruz. (1995). Quality-of-life and behavioral compliance in hemodialysis patients, *Jl Am Soc Nephrology*; 6 (3): 541-541.
- 34) Kimmel PL, Weihs K, Peterson R, Simmens S, Boyle D, Umana W, Veis J, Cruz. (1995). Depression and social support in incident hemodialysis patients, *Jl Am Soc Nephrology*; 5 (3): 459-459.

WORK IN PROGRESS:

1)Yuh J, Reiss D, Weih KL Parent-Adolescent Agreement on the Adjustment of Adolescents of Depressed Parents and its Relations to Informants' Depressive Symptoms in a Clinical Sample – Under Review

- 2) Yuh J, Reiss D, Weihs KL The role of parenting in anxiety and social competence among children of depressed mothers – Under Review
- 3) Larkey, L Weihs, KL et al Qigong/Tai Chi Easy Reduces Cancer-Related Fatigue and BMI in Breast Cancer Survivors Under review.
- 7) Varga CM, Nettles CD, Whitesel AL, Howe GH, Weihs KLW (2012) Short and Long-Run Change in Adult Attachment Security in the Recently Unemployed; Manuscript Under review.
- 8) Lane RD, Hishaw A, Weihs KL Affective Agnosia. - Manuscript in Preparation.
- 9) Curran ML, Young V, Simmens S; Marital Biography and Perceived Support Predict Trajectories of Physical Well-being after Breast Cancer – Manuscript in preparation
- 10) Weihs, KL Howe, GH, Weihs KL, Ayers T, Sandler I: Stressful life events predict externalizing and internalizing symptoms in children aged 9 – 15 after parental job loss. Manuscript in preparation and data analysis in process.
- 11) Weihs KL, Blyler D: Surviving breast cancer: The influence of recent negative life events Manuscript in preparation.
- 12) Weihs KL: Behavioral and psychiatric difficulties in children whose mothers have breast cancer. Data analysis in process.

POPULAR MEDIA IN WHICH SCIENTIFIC WORK HAS BEEN DESCRIBED:

Regular Guest , Cancer Fighters KQTH Radio 104.1

Breast Cancer Husband
By Marc Silver Rodale, 2004

I'm a Teen, My Parent Has Cancer and it Really Sucks! Bonus: A Guide for Parents
By Marc Silver and Maya Silver Rodale, 2013

SCHOLARLY PRESENTATIONS – INVITED (2009 – present):

National

- 1) Weihs, KL; Mulligan, S (2013, August 10) *Survivorship Issues for the Cancer Patient*. Cancer Care and Prevention Conference, UA Cancer Center Network - Flagstaff Medical Center, Flagstaff, AZ.

- 2) Weihs, KL (2012, April 26) *Close Relationships: The Crucible for Cancer Disease Process and the Illness Experience*. Resnick Family Lecture in Psychiatry and Palliative Care, Department of Psychiatry, Grand Rounds, The George Washington University, Washington, D.C.
- 3) Weihs, KL (2010, June 9-13) *Possible Role of Oxytocin and Close Social Relationships in Breast Cancer Progression*, Symposium on Oxytocin and Health Outcomes, Academy of Behavioral Medicine Research, Bodega Bay, CA
- 4) Curran, M. A., *Young, V., & Weihs, K. (2010, March). *Understanding physical symptoms for women with breast cancer: Importance of first marriage and the spouse as confidant*. Invited presentation to The School of Family Life at BYU, Provo, Utah.
- 5) Weihs KL, Irwin M, Lutgendorf S (2009, November 15) *Psychosomatic Processes in Inflammation and Cancer*; 56th Annual meeting of the Academy of Psychosomatic Medicine, Las Vegas, NV.
- 6) Weihs, KL (2009, June 15) *Oxytocin as a Potential Mediator of the Influence of Close Relationships on Breast Cancer Outcomes*, Academy of Behavioral Medicine Research, Keystone, CO.

State

- 1) Weihs, KL (June 1, 2012) *Healthcare Delivery System Change Improves Depression Outcomes at the University of Arizona, Comprehensive Cancer Center*. Conference on Translational Medicine in Arizona: Networks, Partnerships, and Initiatives, sponsored by The Interdisciplinary Health Policy Institute: Northern Arizona University and the Clinical Translation Science Institute: University of Arizona, High Country Conference Center, Northern Arizona University, Flagstaff, Arizona; May 31, June 1-2.

Local (selected)

- 1) Weihs KL, Wiley J, Stanton, A (2013) *Prospective, Longitudinal Study of Emotion Acceptance and Stress Effects on Depression after Breast Cancer*. Poster Presentation for the Frontiers in Science Colloquium, Arizona Health Sciences Center, Tucson, AZ October 29, 2013.
- 2) Weihs, KL (2013) *Survivorship Issues in the Cancer Patient*,” at the “Cancer Care and Prevention: Updates for the Practitioner” conference on Saturday, August 10, 2013, at Los Abrigados Resort, Sedona, Arizona.

- 3) Weihs, KL (2012) Close Relationships: The Crucible for Cancer Disease Process and the Illness Experience Weihs, KL (2012, April 11), Cancer Prevention and Control Conference, Tucson Arizona.
- 2) Weihs, KL(2012, March 18) Scientific Advisory Board, University of Arizona Cancer Center, Supportive Care Research and Clinical Programs.
- 3) Weihs, KL (2011, May 10) Special Topics in Psychiatric Care of Cancer Patients, Hematology- Oncology Fellows seminar, Arizona Cancer Center, Tucson, AZ
- 4) Weihs, KL (2011, April 29) Possible Role of Oxytocin and Close Social Relationships in Breast Cancer Progression; Department of Psychology, University of Arizona.
- 5) Weihs, KL (2011, April 18) Biology of social and emotional processes in cancer patients, Cancer Biology Graduate Seminar, University of Arizona Graduate Interdisciplinary Program, Tucson, AZ.
- 6) Weihs, KL (2011, March) Physiology of Social Relationships: Data from Breast Cancer Patients, Invited presentation for Women's Mental Health Symposium, Tucson, AZ.
- 7) Weihs, KL (2011, Feb) Special Issues in Psychiatric Care of Cancer Patients, Invited presentation, Psychopharmacology Review Course, University of Arizona, Tucson, AZ.
- 8) Curran, M. A., *Young, V., & Weihs, K. (2010, February). Physical symptoms after breast cancer: Do relationships make a difference? Invited presentation to the American Cancer Society Local Office, Tucson, Arizona.
- 9) Depression in the Seriously Ill, Caring for the Seriously Ill: Clinical Updates in Oncology and Palliative Care, University Medical Center, Tucson, AZ; Nov 7-8, 2009.
- 10) Oxytocin as a Potential Mediator of the Influence of Close Relationships on Breast Cancer Outcomes, University of Arizona, College of Medicine, Frontiers in Medical Research Seminars; October 20, 2009
- 11) Collaborative Care: The Role of the Psychiatrist in Primary Care or Cancer Clinics, 17th Annual Psychopharmacology Review, Department of Psychiatry, Univ of Arizona Feb 19, 2009.

**SCHOLARLY PRESENTATIONS – SUBMITTED AND SELECTED THROUGH PEER REVIEW:
(Since 2009)**

- 1) Kogan A, Allen JJB, Weihs KL (2013) Cardiac Vagal Control, Social Functioning and Emotional Adjustment in Breast Cancer; Society for Behavioral Medicine Annual Conference March 20, 2013, San Francisco, CA
- 2) Badger, T.A., Segrin, C., Hepworth, J.T., Pasvogel, A., Weihs, KL. & Lopez, A.M. (Feb.2012) Telephone-Delivered Health Education and Interpersonal Counseling Improve Quality of Life for Latinas With Breast Cancer and Their Supportive Partners APOS 9th Annual Conference. 24 February 2012
- 3) Weihs KL, Lane RD, Stanton AS (2012) Breast Cancer Patients Who Report Greater Security and Support in Close Relationships have Higher Emotional Awareness; Poster Presentation at the 70th Annual Scientific Meeting, Am Psychosomatic Society; Athens, Greece.
- 4) Lane RD, Stanton AL, Fort CL, Hartz VL, Weihs KL (2012, March) Computerized Scoring of Emotional Awareness Content in Writing Samples by Patients with Breast Cancer. Oral presentation at the 70th Annual Scientific Meeting, Am Psychosomatic Society; Athens, Greece.
- 5) Robbins, M. L., Mehl, Matthias, M. R., Smith, H. L., & Weihs, K. L. (2012, June). Linguistic Indicators of Patient, Couple, and Family Adjustment to Breast Cancer. Poster to be presented at the 6th Biennial Cancer Survivorship Research Conference, Arlington, VA.
- 6) Robbins, M. L., Mehl M. R., Lopez, A. M., & Weihs K. L. (2012, January). Emotional Expression in the Daily Conversations of Couples Coping with Breast Cancer. Presentation at the annual meeting of the Society for Personality and Social Psychology, San Diego, CA.
- 7) Robbins, M. L., Mehl M. R., Weihs K. L., & Lopez, A. M. (2012, January). Naturalistic observation of emotional expression in the daily conversations of couples coping with breast cancer. Poster to be presented at the annual meeting of the Society for Personality and Social Psychology, San Diego, CA
- 8) Robbins, M. L., Focella, E. S., Kasle, S., Weihs, K. L., Lopez, A. M., & Mehl, M. R., (2011, June). Naturalistically observed swearing, emotional support and depressive symptoms in women coping with illness. Presented at the annual meeting of the Society for Ambulatory Assessment, Ann Arbor, MI.

- 9) Young VJ, Curran MA, Weihhs KL. (2010). A longitudinal study of physical symptoms by relationship status among breast cancer patients. Poster at APOS 7th Annual Meeting 'Integrating Psychosocial Research and Practice in Quality Cancer Care: Confronting Challenges Together', February 18-21, 2010, New Orleans, LA.
- 10) Povzner A, Allen JJB, O'Donnell R, Brody AE, Weihhs KL. (2009). Resting cardiac vagal control and quality of partner relationship in women newly diagnosed with breast cancer. Poster at Society for Psychophysiological Research 49th Annual Meeting, October 21-24, 2009, Berlin, Germany.
- 11) Weihhs KL, Frank DH, Roe DS, Nassarloo H, Carter CS (2009) Oxytocin administration reduces growth rate of human breast cancer xenografts (MCF7) in SCID mice. Citation Poster APS 67th Annual Scientific Meeting, March 4-7, Chicago, IL.

GRANT AWARDS:

ACTIVE – FEDERAL

1) Emotional Regulation and Depression in Breast Cancer Survivorship

Funding Agency: National Cancer Institute
 Award Type: R01 CA 133081-01A2
 Project Period: 09/05/09-11/01/2014
 Total Grant: \$3,065,528
 Percent Effort: 20%
 Co-Principal Investigators: Karen Weihhs, M.D.
 Annette Stanton, Ph.D.

COMPLETED– FEDERAL

1) Longitudinal Effects of Intimate Partner Relationship Quality on Serum Oxytocin Levels in Newly Diagnosed Breast Cancer Patients

Funding Agency: USA Med Research & Materiel Command, Breast Cancer Research Prgm.
 Award Type/#: W81XWH-04-1-0603 - Idea Award
 Project Period: 7/1/04 – 1/11/11
 Total Grant: \$899, 992
 Percent Effort: 20%
 Principal Investigator: Karen Weihhs, M.D.
 Co-Investigators: Alison Stopeck, M.D.
 Ana Maria Lopez, M.D.
 Amy Waer, M.D.
 Consultants: Ray Nagle, M.D.

2) Vulnerability to Stress Induced Depression Post Job Loss

Funding Agency: National Institutes of Mental Health
 Award Type/#: R01 MH073712
 Project Period: 7/1/06 – 6/30/10
 Total Grant: \$1,386,948

Percent Effort: 10%
Principal Investigator: George Howe, Ph.D.
Co-Investigators: Karen Weihs, M.D.
Francisco Moreno, M.D.
Jenae Neiderheiser, Ph.D.
Consultants: Joel Gelernter, Ph.D.

3) Qigong Effects on Fatigue and Cognitive Function after Treatment for Breast Cancer

Funding Agency: Nat Ctr for Complementary and Alternative Medicine
Award Type/#: U01AT002706
Project Period: 2/1/07 – 1/31/10
Total Grant: \$601,728
Percent Effort: 5%
Principal Investigator: Linda Larkey, Ph.D.
Co-Investigators: Karen Weihs, M.D.
Terry Badger, R.N., Ph.D.
Ana Maria Lopez, M.D.

4) Cancer Control and the Influence of Family

Funding Agency: NIH
Award Type/#: NRSA F33, Ruth L. Kirschstein National Research Service Award for Individual Senior Fellowship Application
Project Period: 3/1/07 – 2/28/10
Total Grant: \$58,886
Percent Effort: 0%
Principal Investigator: Catherine Marshall, Ph.D.
Mentors: Francisco Garcia, M.D.
Karen Weihs, M.D.
Terry Badger, R.N., Ph.D.
Ana Maria Lopez, M.D.

ACTIVE – PRIVATE FOUNDATIONS

1) Latinas with Cancer and the Intimate or Family Partners

Funding Agency: American Cancer Society
Award Type/#: RSG-12-120-01-CPPB
Project Period: 7/1/2012-6/30/17
Total Grant: \$1,340,000 plus indirects (total 1,675,000)
Percent Effort: .01
Principal Investigator: Terry Badger, R.N., Ph.D.
Co-Investigators: Karen Weihs, M.D.
Ana Maria Lopez, M.D.
Chris Segrin, Ph.D.

2) Surviving breast cancer: The dynamics of inflammation, emotion, and family

Funding Agency: American Cancer Society
Award Type/#: Research Scholar Grant
Project Period: 3/1/2013-2/38/16

Total Grant: \$408,319
Percent Effort: 11.6%
Principal Investigator: Emily Butler, Ph.D.
Co-Investigators: Karen Weihs, M.D.
Dave Sbarra, Ph.D.

COMPLETED – PRIVATE FOUNDATION FUNDING

1) Latinas with Cancer and Partners: Telephone Counseling for Improving Quality of Life

Funding Agency: Lance Armstong Foundation
Award Type/#: Survivorship Award
Project Period: 4/1/07 – 3/30/09
Total Grant: \$247,772
Percent Effort: 4%
Principal Investigator: Terry Badger, R.N., Ph.D.
Co-Investigators: Karen Weihs, M.D.
Ana Maria Lopez, M.D.
Chris Segrin, Ph.D.

2) A Longitudinal Examination of Physical Well-being for Women with Breast Cancer: the Impact of Intensity of Treatment, the Spouse as a Confidant, and Acceptance of Emotion

Funding Agency: American Cancer Society
Award Type/#: Institutional Research Grant – Pilot funding
Project Period: 7/1/09 – 6/30/10
Total Grant: \$20,000
Percent Effort: 0%
Principal Investigator: Melissa Curran, PhD.
Co-Investigators: Karen Weihs, M.D.

ACTIVE – INTERNAL INSTITUTIONAL FUNDING

1) Autonomic Physiology of Emotion Regulation and Depression in Breast Cancer Survivorship

Funding Agency: Arizona Cancer Center -Dell Webb Foundation
Award Type/#: Pilot Project Development Award
Project Period: 7/1/13 – 6/30/14
Total Grant: \$30,000
Percent Effort: 0%
Co-Principal Investigator: Karen Weihs, M.D.
Co-Principal Investigator: John Allen, Ph.D.

COMPLETED – INTERNAL INSTITUTIONAL FUNDING

1) Depression in GI Cancer Patients: A Pilot Study

Funding Agency: Arizona Cancer Center SPORE in GI Cancers, Developmental Research Program
Award Type/#: Pilot Project Development Award
Project Period: 1/5/08 – 1/4/09
Total Grant: \$39,864

Percent Effort: 7%
Principal Investigator: Karen Weihs, M.D.

ACTIVE – INDUSTRY SPONSORED

- 1) A multicenter, randomized, double-blind, placebo-controlled, fluoxetine-referenced, parallel-group study to evaluate the efficacy, safety, and tolerability of desvenlafaxine succinate sustained release (DVS SR) in the treatment of children and adolescent outpatients with major depressive disorder (B2061031).

Funding Agency: Pfizer, Inc.
Award Type/#: Site award
Project Period: 7/1/2011-6/30/2013
Total Grant: \$95,009 (\$76,008 direct)
Percent Effort: 2% (this grant is funding my post-doctoral fellow)
Principal Investigator: Karen Weihs, M.D.

- 2) A 6-Month, Open-Label, Multi-Center, Flexible-Dose Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability AND Efficacy of Desvenlafaxine Succinate Sustained-release (DVS SR) Tablets in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (protocol B2060131)

Funding Agency: Pfizer, Inc.
Award Type/#: Site award
Project Period: 7/1/2011-6/30/2013
Total Grant: \$53,351 (\$42,681 direct)
Percent Effort: 2% (this grant is funding my post-doctoral fellow)
Principal Investigator: Karen Weihs, M.D.

COMPLETED – INDUSTRY SPONSORED

SITE PRINCIPAL INVESTIGATOR: CLINICAL RESEARCH - INDUSTRY SPONSORED

- 1) Safety Surveillance Study for Wellbutrin Sustained Release. Multi-site Phase IV Trial.

Funding Agency: Burroughs Wellcome Co.
Project Period: 4/93-12/94
Potential earnings: \$5030/year
Principal Investigator: Karen Weihs, M.D.
Percent Effort: 0%

- 2) A Double-Blind, Placebo-Controlled, Multicenter Study of Fixed Doses of Paroxetine (10, mg, 20 mg & 40mg), Given as a Single Oral Dose Daily, in the Treatment of Panic Disorder.

Funding Agency: SmithKline Beecham Pharmaceuticals
Project Period: 5/93-2/94
Potential earnings: \$16,993/9 months
Principal Investigator: Karen Weihs, M.D.
Percent Effort: 0%

- 3) A Double-Blind, Placebo-Controlled, Parallel Group Study of Paroxetine in the Treatment of Dysthymia. Multi-site Phase IV Trial.

Funding Agency: SmithKline Beecham Pharmaceuticals
Project Period: 2/94-9/94
Potential earnings: \$72,164/7 months
Principal Investigator: Karen Weihs, M.D.
Percent Effort: 0%

4) A Double Blind, Placebo-Controlled Fixed Dose Evaluation of the Safety and Efficacy of Oral Ondansetron in the Treatment of Patients with Panic Disorder. Multi-site Phase III Trial

Glaxo, Inc.
10/94-5/96
\$38,288/year
PI
0% Effort

5) Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of Venlafaxine-Extended Release Capsules in Outpatients with Generalized Anxiety Disorder. Multi-site Phase III Trial

Wyeth-Ayerst Research
9/95-12/96
\$62,942/year
PI
75% Effort 7/96 – 12/96

6) Phase III, Six-Week Double Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Three Fixed Doses of Oral Ziprasidone (CP-88,059-1) (20mg, BID; 60mg, BID; and 100mg, BID) and Haloperidol in the Acute Exacerbation of Schizophrenia & Schizoaffective Disorder. . Phase III Trial

Pfizer, Inc.
9/94-12/96
\$72,756/year
PI
0% Effort

7) Fifty-two Week, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Oral Ziprasidone (CP-88,059-1) (40-80 mg, BID) and Risperidone (3-5 mg, BID) in the Maintenance Treatment of Outpatients with Schizophrenia and Schizoaffective Disorder. . Multi-site Phase III Trial

Pfizer, Inc.
9/94-4/96
\$77,448/7 months
PI
0% Effort

8) Fifty-Two Week, Open Extension Study Evaluating the Safety and Outcome of 40-80 mg BID of Oral CP-88,059 Daily in the Treatment of Subjects Who Have Participated in Previous CP-88,059-1 Clinical Trials.

Pfizer, Inc.
9/94-12/97
\$26,018/year
PI

0% Effort

- 9) A Phase III, Randomized, Multicenter, Open Label Study Evaluating the Toleration and Safety of 3 Days of Treatment with Intramuscular Ziprasidone(20-80 mg Daily) or Haloperidol (up to 40 mg Daily) Followed by 4 Days of Treatment with Oral Ziprasidone or Haloperidol in Subjects with a Diagnosis of Psychotic Disorder.

Pfizer, Inc.

9/96-9/97

\$39,500/year

PI

75% Effort 1/97 – 9/97

- 10) A Double-Blind Comparison of Fixed Dose Sertraline and Placebo in the Treatment of Premenstrual Syndrome; Multi-site Phase IV Trial.

Pfizer, Inc.

9/96-9/97

\$79,489/year

PI

0% Effort

- 11) A Randomized, Double-Blind, Fixed Dose Comparison of 20, 40, and 60 mg daily of Paroxetine and Placebo in the Treatment of Generalized Social Phobia; Multi-site Phase IV Trial.

SmithKline Beecham Pharmaceuticals

12/96-12/97

\$52,953/year

PI

0% Effort

- 12) A Double-blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release Paroxetine in the Treatment of Panic Disorder; Multi-site Phase IV Trial.

SmithKline Beecham Pharmaceuticals

9/96-12/98

\$80,760/year

PI

35% Effort 10/97 – 12/98

- 13) A Double-Blind Trial of Three Fixed Doses of Nefazodone and Placebo in the Treatment of Patients with Panic Disorder. Multi-Site Phase IV Trial.

Bristol-Myers Squibb Pharmaceutical Research Institute

5/97-12/98

\$97,667/year

PI

40% Effort 10/97 – 12/98

- 14) A Randomized, Double-blind, Placebo Substitution Trial of the Efficacy of Nefazodone in the Long Term Continuation Treatment of Patients with Panic Disorder. Multi-site Phase IV Trial.

SmithKline Beecham Pharmaceuticals

12/96 - 6/99

\$24,928/year

PI

24% Effort 1/99 – 6/99

- 15) A Multicenter, Double-blind, Randomized Pilot Study Comparing the Safety and Efficacy of Wellbutrin (Bupropion HCL) Sustained Release and Paroxetine in the Treatment of Elderly Outpatients with Moderate to Severe Recurrent Major Depression. Phase IV Trial.

Glaxo Wellcome

12/96-12/97

\$79,794/year

PI

15% Effort

- 16) An Eight-Week Multicenter, Parallel-Group, Double Blind, Placebo-Controlled Study of Sertraline in the Treatment of Elderly Outpatients with Major Depression. Multi-site Phase IV Trial

Pfizer, Inc.

8/97 - 8/99

\$80,5394/year

PI

51% Effort 1/99 – 6/99

- 17) A Double Blind, Placebo Controlled, Multi-center Study Evaluating the Efficacy and Safety of SR 46349 in Outpatients with Major Depression. Phase II Trial

Sanofi

12/97 - 12/98

\$75,634/year

PI

75% Effort 7/99 – 6/00

- 18) A Multi-center Placebo-Controlled Study of Bupropion Hydrochloride Sustained Release for the Prevention of Relapse/Recurrence in Subjects Whose Depression Responded to Treatment with Bupropion Hydrochloride Sustained Release. Phase IV Trial

Glaxo Wellcome, Inc.

1/98 - 12/2000

\$114,718/year

PI

75% Effort

- 19) An Open-Label Evaluation of the Efficacy, Safety and Dosing of Citalopram in Outpatients with Depression. Phase IV Trial

Forest Laboratories, Inc.

6/98 - 6/99

\$22,360/year

PI

0% Effort

- 20) An Open-Label Extension of Citalopram Treatment in Outpatients with Depression Phase IV Trial

Forest Laboratories, Inc.

9/98 - 9/99

\$12,000/year

PI
0% Effort

- 21) A Multicenter Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Bupropion Hydrochloride Sustained Release and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression. Phase IV Trial

Glaxo Wellcome Inc.
9/98 - 1/2000
\$162,664/year
PI
0% Effort

- 22) A Multicenter Randomized Double Blind, Placebo Controlled Trial of Sertraline for Acute Treatment of DSM-IV Generalized Social Phobia in Outpatients. Phase IV Trial

Pfizer, Inc.
4/99-8/01
\$74,819/year
PI
0% Effort

- 23) A Multicenter, Double-Blind, Placebo and Paroxetine Controlled, Randomized, Flexible Dose Trial of Nefazodone ER in the Treatment of Depressed Patients. Phase IV Trial

Bristol-Myers Squibb, Pharmaceutical Research Institute.
4/99 – 10/2000
\$184,193/year
PI
75% Effort 6/00 – 10/01

- 24) A Double Blind, Placebo-Controlled Study of Flexible Dose of Venlafaxine ER in Adult Outpatients with Generalized Social Anxiety Disorder. Phase IV Trial

Wyeth-Ayerst Research.
11/99 – 10/01
\$60,981/year
PI
30% Effort 10/00 – 10/01

- 25) A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Fluvoxamine CR in the Treatment of Generalized Social Anxiety Disorder. Phase IV Trial

Solvay.
8/99- 9/02
\$51,897/year
PI
0% Effort

- 26) A Randomized, Double-Blind, Placebo-Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Social Anxiety Disorder. Multi-site Phase IV Trial

SmithKline Beecham.
11/98 – 9/99
\$88,223/10 months

PI
0% Effort

27) Sustained Efficacy Study of Pregabalin in Patients With Panic With or Without Agoraphobia. Phase III Trial

ParkeDavis.
2/2000- 2/2001
\$42,865/year
PI
0% Effort

28) A Multicenter, 10-Week, Randomized, Double Blind, Placebo-Controlled, Flexible Dose Outpatient Study of Sertraline in Children and Adolescents with Major Depression. Phase IV Trial and Open Label Extension

Pfizer Inc.
9/2000 – 12/2001
\$271,037
PI
40% Effort 6/01 – 10/01

29) A Double-Blind, Placebo Controlled, Parallel Group, Flexible-Dose Study of Venlafaxine ER in Adolescent Outpatients with Social Anxiety Disorder. Phase IV Trial

Wyeth-Ayerst Research.
4/2000 - 12/2001
\$13,229/year
PI
0% Effort

30) Duloxetine Versus Placebo and Paroxetine in the Acute Treatment of Major Depression. Phase III

Eli Lilly and Company
2/2000 – 6/2001
\$98,381/year
PI
40% Effort 10/00 – 6/01

31) A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Study to Evaluate the Efficacy and Tolerability of Sertraline in Subjects Diagnosed with DSM-IV Generalized Anxiety Disorder. Multi-site Phase IV Trial

The Clinical Innovation Group
3/2000 – 12/31/02
\$164,560/year
PI
0% Effort

32) A Double-Blind, Placebo-Controlled Comparative Efficacy Study of Venlafaxine ER and Sertraline in Producing Remission in Outpatients with Major Depression Disorder. Multi-site Phase IV Trial

Wyeth-Ayerst Research.
6/2000 – 12/2001
\$69,123/year

PI
0% Effort

33) A Multicenter, Double-Blind, Placebo-Controlled Trial of Two Dose Ranges of Nefazodone in the Treatment of Children and Adolescents with a Major Depressive Episode. Phase IV Trial

Bristol-Meyers Squibb.
11/2000 – 10/2001
\$16,720/year
PI
0% Effort

34) A Double-blind, Placebo Controlled, Fixed-dosage Study Comparing the Efficacy and Tolerability of Paroxetine CR and Citalopram to Placebo in the Treatment of Major Depressive Disorder with Anxiety.

GlaxoSmithKline
4/2002 – 11/2002
\$70,065/ 7 months
PI
0% Effort

35) A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients with Generalized Anxiety Disorder. Phase IV Trial

GlaxoSmithKline
8/2001 – 2/2002
\$92,287
PI
0% Effort

36) An Evaluation of the Long Term Efficacy and Prevention of Relapse by Venlafaxine-ER in Adult Outpatients with Panic Disorder Phase IV Trial

Wyeth-Ayerst
\$55,500
9/2001 – 12/2002
PI
75% Effort 10/01 – 4/02

37) A Phase IIB, Six-Week, Double-Blind, Placebo-and Paroxetine-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder and Associated Somatic Symptoms, Phase III Trial

Pfizer, Inc.
\$154,411
11/2001 – 12/2002
PI
75% Effort 5/02 – 12/02

38) A Seven-Week, Double Blind, Extension of: A Phase IIB, Six-Week, Double-Blind, Placebo-and Paroxetine-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder and Associated Somatic Symptoms. Phase III Trial

Pfizer, Inc.

11/2001 – 3/2003

PI

0% Effort

- 39) A Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Long Term Safety, Efficacy and Prevention of Relapse in Adult Outpatients with Panic Disorder who Respond to open-label Venlafaxine ER

Wyeth-Ayerst

12/2001 – 6/2002

\$146, 172

PI

0% Effort

- 40) An Eight-Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and efficacy of 2 Doses of CP-448,187 (1.5 and 3mg) and Paroxetine in Subjects with Major Depressive Disorder

Pfizer, Inc.

12/2001 – 12/2002

\$125,266

PI

0% Effort

- 41) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Safety and Tolerability of 60 mg Buspirone Hydrochloride Extended Release Compared to Placebo in Patients with Generalized Anxiety Disorder Who Have Stable Disease Characteristics

Biovail Laboratories, Inc.

9/2001 – 10/2002

PI

0% Effort

- 42) A 6 ½ Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 300 mg/day of Extended-Release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder

GlaxoSmithKline

9/2001 – 9/2002

\$74,944

PI

0% Effort

- 43) A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of Two Doses of MK-0869 in the Treatment of Patients with Major Depressive Disorder, Protocol 061

Merck & Co, Inc

2/2002 – 12/2003

\$333,198

PI

68% Effort

- 44) A Double-Blind, Multicenter, Placebo- and Active-Controlled, Acute and Extension Study of Two doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder, Protocol 062
Merck & Co, Inc
9/2002 – 12/2003
\$206,753
PI
75% Effort 1/03 – 12/03
- 45) A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (40-60-80mg) Versus Placebo in Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period.
GlaxoSmithKline
4/2003 – 8/2004
\$102,156
PI
0% Effort
- 46) A Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period
GlaxoSmithKline
2/2003 – 10/2004
#337,017
PI
100% Effort 12/03 – 6/04
- 47) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Flexible Dose of DVS-233-SR in Adult Outpatients with Major Depressive Disorder.
Wyeth Research
7/2003 -6/2004
\$70,781
PI
0% Effort
- 48) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of a Flexible Dose of DVS-233-SR and Venlafaxine ER in Adult Outpatients with Major Depressive Disorder.
Wyeth Research
4/2004 – 12/2005
\$184,307
PI
0% Effort
- 49) A 52-week, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the long-term efficacy, tolerability and safety of agomelatine 25 and 50 mg in the prevention of relapse of Major Depressive Disorder following open-label treatment of 16-24 weeks
Novartis
12/15/07 – 12/21/10
\$28,000
Co-PI

0% Effort

50) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fluoxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder

Pfizer, Inc.

7/1/2011 – 6/30/15

\$184,000

PI

1% Effort